Diamyd Medical AB (publ) reported earnings results for the third quarter and nine months ended May 31, 2024. For the third quarter, the company reported sales was SEK 0.052 million compared to SEK 0.148 million a year ago. Revenue was SEK 0.864 million compared to SEK 5.83 million a year ago. Net loss was SEK 40.08 million compared to SEK 20.64 million a year ago. Basic loss per share from continuing operations was SEK 0.4 compared to SEK 0.3 a year ago.
For the nine months, sales was SEK 0.111 million compared to SEK 0.472 million a year ago. Revenue was SEK 3.01 million compared to SEK 8.44 million a year ago. Net loss was SEK 102.11 million compared to SEK 78.56 million a year ago. Basic loss per share from continuing operations was SEK 1.1 compared to SEK 1 a year ago.